Navigation Links
Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
Date:7/7/2010

EAST NORRITON, Pa., July 7 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN) today announced that it has appointed Sunita B. Sheth, M.D., to the position of Chief Medical Officer, Vice President, Clinical and Regulatory Affairs. In this role, Dr. Sheth will be responsible for developing clinical development strategies, implementing clinical trials, and providing clinical translation insights to preclinical pipeline programs.

"We are extremely pleased to add Dr. Sheth to the Tengion team," stated Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion. "Her broad experience in multiple therapeutic areas, deep knowledge of early and late stage clinical development, and commitment to patient care will be invaluable to Tengion as we continue to advance our platform and product candidates."

Dr. Sheth most recently served as Vice President, Specialty Care Business Unit, for Pfizer as part of its acquisition of Wyeth. Prior to that, she spent four years at Wyeth, most recently as Vice President, Cardiovascular, Metabolic and Infectious Diseases. Before joining Wyeth, she held positions of increasing responsibility at AstraZeneca and GlaxoSmithKline since joining the industry in 1997. Her pharmaceutical development leadership experience covers multiple therapeutic areas and phases of development including approval of several INDs for drugs as well as the biologics FIX mab and OAP-189; the global regulatory submission of ximelagatran for multiple indications; and approval of an sNDA for Tygacil. 

"This is an exciting time for Tengion and I am very much looking forward to working closely with the management team to advance the company's pipeline," stated Dr. Sheth. "Tengion's Organ Regeneration Platform™ provides a unique opportunity to bring novel therapies and clinical advances to patients in need."

Dr. Sheth earned her B.A. and M.D. degrees from Brown University and completed fellowships in Hematology/Oncology at Brown and Temple University. She maintains an adjunct professorship at Temple University Medical School.

Tengion's lead program, the Neo-Urinary Conduit™, is currently in a Phase 1 clinical trial in patients with bladder cancer. Tengion expects to report key data for its lead discovery program, the Neo-Kidney Augment™, later this year.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform that enables us to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Our product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in March 2010 for its lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder issue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.

Forward-Looking Statements

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to: (i) our plans to develop and commercialize our product candidates, including our Neo-Urinary Conduit; and (ii) our ongoing and planned preclinical studies and clinical trials. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and the company's business is subject to significant risk and uncertainties, and there can be no assurance that its actual results will not differ materially from its expectations. These risks and uncertainties include, among others: (i) we may have difficulty enrolling patients in our clinical trials, including our Phase I clinical trial for our Neo-Urinary Conduit; (ii) patients enrolled in our clinical trials may experience adverse events related to our product candidates, which could delay our clinical trials or cause us to terminate the development of a product candidate; and (iii) we may be unable to progress our product candidates that are undergoing preclinical testing into clinical trials. For further information with respect to factors that could cause the company's actual results to differ materially from expectations, reference is made to the reports the company filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and the company disclaims any intention or responsibility for updating predictions or expectations contained in this release.


'/>"/>
SOURCE Tengion Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. West Pharmaceutical Services, Inc. Appoints New Director
7. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
8. Curemark Appoints Preeminent Pediatrics Gastroenterologist
9. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... de marzo de 2017   VWR ... soluciones de productos y servicios para clientes de ... adquirido EPL Archives, Inc., una organización de servicios ... todo el ciclo de vida de investigación de ... de archivo, almacenamiento de documentos y servicios complementarios. ...
(Date:3/22/2017)... 22, 2017 Ampio Pharmaceuticals, Inc. (NYSE ... Ampion™, a low molecular weight fraction of human ... it is re-issuing its previous release that was made ... that are required under the NYSE MKT Company ... additional disclosures along with the previously disclosed update ...
(Date:3/22/2017)... New Jersey,s hospitals ... and saved $641 million in healthcare costs between 2012 ... quality improvement program. The results reflect ... part of a national initiative from the U.S. Department ... Jersey Hospital Association and its affiliate, the Health Research ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... Natural Subsistence, a company known for ... and nutrition, announced its product Leyzene is now available for purchase on Go4ItNutrition.com, ... that help people improve all aspects of their health so they can live ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of ... the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient ... contributed not only to the association, but also to the Health Care Quality and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An ... http://www.fdanews.com/mdclineval                  , How will the new EU MDR language change ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy ... of published author Bonetta Rose, a wife, mother and grandmother committed to sharing her ... Faith Publishing, Bonetta Rose‘s new book presents actual events in the life of her ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful ... “A Respectful Response To Atheist Manifesto” is the creation of published author Richard ... Nancy, for sixty years. He holds graduate degrees from Kent State University and ...
Breaking Medicine News(10 mins):